Suppr超能文献

身体组成:胃癌新辅助化疗降期及术后并发症的关键因素。

Body composition: a crucial factor in downstaging and postoperative complications of neoadjuvant chemotherapy for gastric cancer.

作者信息

Jin Zhuanmei, Chen Min, Yang Qinglin, Yao Changyu, Li Yanting, Zhang Taohua, Lai Min, Li Shuangxi, Ding Lipeng, Yuan Wenzhen

机构信息

The First Clinical Medical College of Lanzhou University, Lanzhou, China.

Department of Orthopedics, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

Front Nutr. 2024 Nov 20;11:1481365. doi: 10.3389/fnut.2024.1481365. eCollection 2024.

Abstract

BACKGROUND

Postoperative complications may lower the quality of life of patients, consequently leading to a reduction in their overall survival (OS). In our previous investigations, we found that patients with gastric cancer (GC) with postoperative complications who underwent direct surgery had a significantly lower OS than patients without complications. We observed no significant difference in OS among patients who underwent neoadjuvant chemotherapy (NAC), regardless of complications. We propose that for patients who underwent reoperation following NAC, downstaging (reduction of clinical stage) and postoperative complications exerted contrasting effects on the OS. Further, we hypothesize that post-NAC downstaging and the absence of postoperative complications lead to a longer OS.

METHODS

We conducted a retrospective analysis to collect the clinical data of patients with GC who underwent surgery after receiving NAC at the First Hospital of Lanzhou University from January 2016 to December 2022. Based on the presence of a post-NAC downstaging period and postoperative complications, we categorized the patients into group A (downstaging without complications), group B (downstaging with complications), group C (non-downstaging with complications), and group D (non-downstaging without complications). First, we assessed the OS disparity between the groups. Subsequently, we performed a comparative analysis of the body composition and hematological indexes of patients from the four groups.

RESULTS

We included 295 patients in the study and categorized them into four subgroups: group A comprised 83 patients (28.1%), group B comprised 32 patients (10.8%), group C comprised 83 patients (28.1%), and group D comprised 97 patients (32.9%). Group A patients had the longest OS of 40.1 ± 20.53, whereas group C patients had the shortest OS of 32.15 ± 25.09. The OS of patients in the other two groups was between these values. Pairwise comparisons revealed significant differences between the OS of group A patients and that of groups C (32.15 ± 25.09) and D (33.06 ± 20.89) patients ( < 0.05). The skeletal mass index (SMI) and skeletal mass area (SMA) were highest in group A, lowest in group C, higher in group A (SMI: 45.05 ± 7.44, SMA: 128.88 ± 22.67) than in group C (SMI: 41.61 ± 8.17, SMA: 115.56 ± 26.67) ( < 0.05), and higher in group D (SMI: 44.94 ± 6.87, SMA: 127.05 ± 23.09) than in group C ( < 0.05). However, we observed no significant difference between the SMI and SMA of groups B (SMI: 42.91 ± 9.68, SMA: 120.76 ± 30.51) and D ( > 0.05). With respect to hematological indexes, the prognostic nutritional index (PNI) was highest in group A and lowest in group C. The PNI in group A (417.89 ± 37.58) was significantly higher than that in group C (397.62 ± 47.56) ( < 0.05), and it was also higher in group D (410.76 ± 4.28) than in group C ( < 0.05). However, we observed no significant difference between the PNI in groups B (402.57 ± 53.14) and D ( > 0.05).

CONCLUSION

Patients with advanced GC who experienced post-NAC downstaging and no postoperative complication had the longest OS. Patients with better body composition demonstrated more significant downstaging, fewer postoperative complications, and a longer OS.

摘要

背景

术后并发症可能会降低患者的生活质量,进而导致其总生存期(OS)缩短。在我们之前的研究中,我们发现接受直接手术的胃癌(GC)术后有并发症的患者的OS明显低于无并发症的患者。我们观察到接受新辅助化疗(NAC)的患者的OS无显著差异,无论有无并发症。我们提出,对于NAC后接受再次手术的患者,降期(临床分期降低)和术后并发症对OS产生相反的影响。此外,我们假设NAC后降期且无术后并发症会导致更长的OS。

方法

我们进行了一项回顾性分析,以收集2016年1月至2022年12月在兰州大学第一医院接受NAC后接受手术的GC患者的临床数据。根据NAC后是否存在降期及术后并发症,我们将患者分为A组(降期无并发症)、B组(降期有并发症)、C组(未降期有并发症)和D组(未降期无并发症)。首先,我们评估了各组之间的OS差异。随后,我们对四组患者的身体成分和血液学指标进行了比较分析。

结果

我们纳入了295例患者进行研究,并将他们分为四个亚组:A组包括83例患者(28.1%),B组包括32例患者(10.8%),C组包括83例患者(28.1%),D组包括97例患者(32.9%)。A组患者的OS最长,为40.1±20.53,而C组患者的OS最短,为32.15±25.09。其他两组患者的OS介于这些值之间。两两比较显示,A组患者的OS与C组(32.15±25.09)和D组(33.06±20.89)患者的OS之间存在显著差异(P<0.05)。骨骼质量指数(SMI)和骨骼质量面积(SMA)在A组最高,在C组最低,A组(SMI:45.05±7.44,SMA:128.88±22.67)高于C组(SMI:41.61±8.17,SMA:115.56±26.67)(P<0.05),D组(SMI:44.94±6.87,SMA:127.05±23.09)也高于C组(P<0.05)。然而,我们观察到B组(SMI:42.91±9.68,SMA:120.76±30.51)和D组的SMI和SMA之间无显著差异(P>0.05)。关于血液学指标,预后营养指数(PNI)在A组最高,在C组最低。A组的PNI(417.89±37.58)显著高于C组(397.62±47.56)(P<0.05),D组(410.76±4.28)也高于C组(P<0.05)。然而,我们观察到B组(402.57±53.14)和D组的PNI之间无显著差异(P>0.05)。

结论

经历NAC后降期且无术后并发症的晚期GC患者的OS最长。身体成分较好的患者降期更显著,术后并发症更少,OS更长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1a9/11614600/65a357c0225e/fnut-11-1481365-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验